Restricted accessResearch articleFirst published online 2025-7
Multicenter randomized controlled trial to assess the effectiveness of PASSEO-LUX DCB ® drug coated balloon compared to plain balloon angioplasty of arteriovenous fistulae for hemodialysis: Two-years results
To compare primary patency after angioplasty with drug-coated balloon (DCB)-Passeo-18Lux, BIOTRONIK versus uncoated balloon in dysfunctional peripheral vascular access (PVA) for hemodialysis.
Material and methods:
A total of 133 patients from four hospitals were randomized to receive DCB or plain old balloon angioplasty (POBA) after satisfactory treatment (residual stenosis <30%) with high pressure balloon (HPB). The primary endpoint was clinical patency of PVA 2 years after angioplasty. Secondary endpoints included the relationship between the location of stenosis and patency and also, other covariates. Mortality at 2 years was compared between both groups.
Results:
Patency measured in days after angioplasty was higher in fistulae dilated with DCB than HPB. Kaplan-Meier survival curves showed the next percent of success (free time restenosis) after DCB versus POBA at 6 months—77.1% versus 58.2% (160.41–143.72 days until restenosis), 12 months—51.4% versus 44.3% (274.1–237.23), 18 months—38.6% versus 38% (350.74–305.18), and 24 months—37.1% versus 30.4% (419.04–369.1). At 6 months, this difference was statistically significant (p = 0.018), but not at 12 (p = 0.225), 18 (p = 0.471), or 24 months (p = 0.236). Mortality was similar in both groups.
Conclusions:
DCB angioplasty resulted in superior target lesion primary patency (TLPP)-free survival at 6 months of follow-up. No significant improvements in TLPP-free survival long term were observed. Mortality observed at 1 and 2 years was similar in DCB and POBA: there was no significant difference, and a safety study demonstrated no difference between the two groups (complications and mortality): DCB is safe to use in stenosis treatment in patients who are PVA carriers.
Level of evidence:
Level Ia, therapeutic study, RCT. EBM ratings will be based on a scale of 1–5.
IbeasJRoca-TeyRVallespínJ, et al. Guía Clínica Española del Acceso Vascular para Hemodiálisis. Nefrología2017; 37(1): 1–191.
2.
RoccoMDaugirdasJTDepnerTA, et al. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis2015; 66(5): 884–930.
3.
LeeTHaqNU.New developments in our understanding of neointimal hyperplasia. Adv Chronic Kidney Dis2015; 22(6): 431–437.
4.
Roy-ChaudhuryPSpergelLMBesarabA, et al. Biology of arteriovenous fistula failure. J Nephrol2007; 20(2): 150–163.
5.
JiaXZhangJZhuangB, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Interv2016; 9(18): 1941–1949.
6.
KatsanosKKitrouPSpiliopoulosS, et al. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and bayesian network meta-analysis of randomized controlled tri. J Endovasc Ther2016; 23(6): 851–863.
7.
ScheinertDMicariABrodmannM, et al. Drug-coated balloon treatment for femoropopliteal artery disease: the IN.PACT global study long lesion imaging cohort. Circ Cardiovasc Interv2018; 11(10): 1–10.
8.
TepeGSchnorrBAlbrechtT, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv2015; 8(1): 102–108.
9.
KinstnerCMLammerJWillfort-EhringerA, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. JACC Cardiovasc Interv2016; 9(13): 1386–1392.
10.
KitrouPMPapadimatosPSpiliopoulosS, et al. Paclitaxel-coated balloons for the treatment of symptomatic central venous stenosis in dialysis access: results from a randomized controlled trial. J Vasc Interv Radiol2017; 28(6): 811–817.
11.
Moreno-SánchezTMoreno-RamírezMMachancosesFH, et al. Efficacy of paclitaxel balloon for hemodialysis stenosis fistulae after one year compared to high-pressure balloons: a controlled, multicenter, randomized trial. Cardiovasc Intervent Radiol2020; 43(3): 382–390.
LučevJBreznikSDinevskiD, et al. Endovascular treatment of haemodialysis arteriovenous fistula with drug-coated balloon angioplasty: a single-centre study. Cardiovasc Intervent Radiol2018; 41(6): 882–889.
14.
HaaveTRManstad-HulaasFBrekkenR.Treatment of restenosis in radiocephalic arteriovenous hemodialysis fistulas: percutaneous transluminal angioplasty or drug-coated balloon. Acta Radiol2019; 60(11): 1584–1589.
15.
HongsakulKBannangkoonKRookkapanS, et al. Paclitaxel-coated balloon angioplasty for early restenosis of central veins in hemodialysis patients: a single center initial experience. Korean J Radiol2018; 19(3): 410–416.
16.
TrerotolaSOLawsonJRoy-ChaudhuryP, et al. Drug coated balloon angioplasty in failing AV fistulas: a randomized controlled trial. Clin J Am Soc Nephrol2018; 13(8): 1215–1224.
17.
TrerotolaSOSaadTFRoy-ChaudhuryP.The Lutonix AV randomized trial of paclitaxel-coated balloons in arteriovenous fistula stenosis: 2-year results and subgroup analysis. J Vasc Interv Radiol2020; 31(1): 1–14.e5.
18.
SwinnenJJHitosKKairaitisL, et al. Multicentre, randomised, blinded, control trial of drug-eluting balloon vs Sham in recurrent native dialysis fistula stenoses. J Vasc Access2019; 20(3): 260–269.
19.
DariushniaSRWalkerTGSilberzweigJE, et al. Quality improvement guidelines for percutaneous image-guided management of the thrombosed or dysfunctional dialysis circuit. J Vasc Interv Radiol2016; 27(10): 1518–1530.
20.
KitrouPMSpiliopoulosSKatsanosK, et al. Paclitaxel-coated versus plain balloon angioplasty for dysfunctional arteriovenous fistulae: one-year results of a prospective randomized controlled trial. J Vasc Interv Radiol2015; 26(3): 348–354.
21.
RoosenLJKaramermerYVosJA, et al. Paclitaxel-coated balloons do not prevent recurrent stenosis in hemodialysis access fistulae: results of a randomized clinical trial. Ital J Vasc Endovasc Surg2017; 24: 35–40.
22.
IraniFGTanBS.Drug coated balloons: are they the holy grail for dysfunctional dialysis arteriovenous fistulas?Cardiovasc Intervent Radiol2021; 44(3): 516–517.
23.
BjörkmanPWeseliusE-MKokkonenT, et al. Drug-coated versus plain balloon angioplasty in arteriovenous fistulas: a randomized, controlled study with 1-year follow-up (the Drecorest Ii-study). Scand J Surg2019; 108(1): 61–66.
24.
LiaoMTChenMKHsiehMY, et al. Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: a systematic review and meta-analysis of randomized controlled trials. PLoS One2020; 15(4): 1–16.
25.
TherasseECatyVGilbertP, et al. Safety and efficacy of paclitaxel-eluting balloon angioplasty for dysfunctional hemodialysis access: a randomized trial comparing with angioplasty alone. J Vasc Interv Radiol2021; 32(3): 350–359.e2.
26.
KimJWKimJHByunSS, et al. Paclitaxel-coated balloon versus plain balloon angioplasty for dysfunctional autogenous radiocephalic arteriovenous fistulas: a prospective randomized controlled trial. Korean J Radiol2020; 21(11): 1239–1247.
27.
LooksteinRAHaruguchiHOurielK, et al. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas. N Engl J Med2020; 383(8): 733–742.
28.
YinYShiYCuiT, et al. Efficacy and safety of paclitaxel-coated balloon angioplasty for dysfunctional arteriovenous fistulas: a multicenter randomized controlled trial. Am J Kidney Dis2021; 78(1): 19–27.e1.
29.
ArabiMSalmanRAlharbiA, et al. Paclitaxel-coated balloons compared to plain balloon angioplasty in the management of dysfunctional arteriovenous fistulae: a single-center randomized clinical trial. Saudi J Kidney Dis Transplant2021; 32(1): 118–127.
30.
PangSYCAu-YeungKCLLiuGYL, et al. Randomized controlled trial for paclitaxel-coated balloon versus plain balloon angioplasty in dysfunctional hemodialysis vascular access: 12-month outcome from a nonsponsored trial. Ann Vasc Surg2021; 72: 299–306.
31.
KarunanithyNRobinsonEJAhmadF, et al. A multicenter randomized controlled trial indicates that paclitaxel-coated balloons provide no benefit for arteriovenous fistulas. Kidney Int2021; 100(2): 447–456.
32.
FranssonTGottsäterAAbdulrasakM, et al. Drug-eluting balloon (DEB) versus plain old balloon angioplasty (POBA) in the treatment of failing dialysis access: a prospective randomized trial. J Int Med Res2022; 50(3): 3000605221081662.
33.
HoldenAHaruguchiHSuemitsuK, et al. IN.PACT AV access randomized trial: 12-month clinical results demonstrating the sustained treatment effect of drug-coated balloons. J Vasc Interv Radiol2022; 33(8): 884–894.e7.
34.
MaleuxGVander MijnsbruggeWHenroteauxD, et al. Multicenter, randomized trial of conventional balloon angioplasty versus paclitaxel-coated balloon angioplasty for the treatment of dysfunctioning autologous dialysis fistulae. J Vasc Interv Radiol2018; 29(4): 470–475.e3.
35.
CaoZLiJZhangT, et al. Comparative effectiveness of drug-coated balloon vs balloon angioplasty for the treatment of arteriovenous fistula stenosis: a meta-analysis. J Endovasc Ther2020; 27(2): 266–275.
36.
FongKYZhaoJJTanE, et al. Drug coated balloons for dysfunctional haemodialysis venous access: a patient level meta-analysis of randomised controlled trials. Eur J Vasc Endovasc Surg2021; 62(4): 610–621.
37.
HuHTanQWangJ, et al. Drug-coated balloon angioplasty for failing haemodialysis access: meta-analysis of randomized clinical trials. Br J Surg2021; 108(11): 1293–303.
38.
CarvalhoTCarvalhoDMarujoP, et al. A cost-effective analysis of drug-eluting balloon in highly recurrent stenosis on dialysis vascular access. Port J Nephrol Hypertens2021; 34(4): 243–248.
39.
LuoCLiangMLiuY, et al. Paclitaxel coated balloon versus conventional balloon angioplasty in dysfunctional dialysis arteriovenous fistula: a systematic review and meta-analysis of randomized controlled trials. Ren Fail2022; 44(1): 155–170.
40.
KitrouPMKatsanosKSpiliopoulosS, et al. Drug-eluting versus plain balloon angioplasty for the treatment of failing dialysis access: final results and cost-effectiveness analysis from a prospective randomized controlled trial (NCT01174472). Eur J Radiol2015; 84(3): 418–423.
41.
SpeckUCremersBKelschB, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?Circ Cardiovasc Interv2012; 5(3): 392–400.
42.
Fernández-ParraRLabordaALahuertaC, et al. Pharmacokinetic study of paclitaxel concentration after drug-eluting balloon angioplasty in the iliac artery of healthy and atherosclerotic rabbit models. J Vasc Interv Radiol2015; 26(9): 1380–1387.e1.
43.
ZorgerNMankeCLenhartM, et al. Peripheral arterial balloon angioplasty: effect of short versus long balloon inflation times on the morphologic results. J Vasc Interv Radiol2002; 13(4): 355–359.
44.
ZellerTRastanAMacharzinaR, et al. Novel approaches to the management of advanced peripheral artery disease: perspectives on drug-coated balloons, drug-eluting stents, and bioresorbable scaffolds. Curr Cardiol Rep2015; 17(9): 624.
45.
MozaffarianDBenjaminEJGoAS, et al. Heart disease and stroke statistics—2016 update. Circulation2016; 133(4): e38–e360.
46.
YazdaniSKPachecoENakanoM, et al. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv2014; 83(1): 132–140.
47.
ClarkC.Exposure risks with cytotoxic drugs. Hosp Pharm Eur2010; 49: 15–16.
48.
IraniFGTeoTKBTayKH, et al. Hemodialysis arteriovenous fistula and graft stenoses: randomized trial comparing drug-eluting balloon angioplasty with conventional angioplasty. Radiology2018; 289(1): 238–247.
49.
D’CunhaPTBesarabA.Vascular access for hemodialysis: 2004 and beyond. Curr Opin Nephrol Hypertens2004; 13(6): 623–629.
50.
TanZChanSXJMDa ZhuangK, et al. Recurrent stenoses in arteriovenous fistula (PVA) for dialysis access: cuttIng ballooN angioplaSTy combined wITh paclitaxel drUg-coaTed balloon angioplasty, an observatIONal study (INSTITUTION Study). Cardiovasc Intervent Radiol2022; 45(5): 646–653.
51.
ZhengJCuiJMeiyan QingJ, et al. Safety and effectiveness of combined scoring balloon and paclitaxel-coated balloon angioplasty for stenosis in the hemodialysis access circuit. Diagn Interv Imaging2019; 100(1): 31–37.
52.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc2018; 7: e011245.
53.
TangTYSoonSXYYapCJQ, et al. Utility of sirolimus coated balloons for salvaging dysfunctional arteriovenous fistulae: one year results from the MATILDA trial. Eur J Vasc Endovasc Surg2021; 62: 316–317.
54.
TangTYSoonSXYapCJ, et al. Endovascular salvage of failing arterio-venous fistulas utilising sirolimus eluting balloons: six months results from the ISABELLA trial. J Vasc Access2023; 24(5): 1008–1017.
55.
TanCWTanRYPangSC, et al. Single-center prospective pilot study of sirolimus drug-coated balloon angioplasty in maintaining the patency of thrombosed arteriovenous graft. J Vasc Interv Radiol2021; 32(3): 369–375.
56.
Moreno-SanchezT.Paclitaxel and cutting balloon: a new strategy to avoid arteriovenous fistula restenosis?Cardiovasc Intervent Radiol2022; 45(5): 654–655.
57.
DinhKLimmerAMParavastuSCV, et al. Mortality after paclitaxel-coated device use in dialysis access: a systematic review and meta-analysis. J Endovasc Ther2019; 26(5): 600–612.
58.
LazaridesMKChristainaEAntoniouGA, et al. Plain versus paclitaxel-coated balloon angioplasty in arteriovenous fistula and graft stenosis: an umbrella review. J Vasc Access2022; 23(6): 981–988.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
